Telemonitoring for patients with chronic coronary syndrome
Usefulness of a Telemonitoring System to Optimize Continuity of Care From Cardiology to Primary Care in Patients With Chronic Coronary Syndrome
This study tests if a new telemonitoring program can help people with chronic coronary syndrome stay active and healthy better than regular check-ups.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years to 72 Years |
| Sex | All |
| Sponsor | Catcronic Salut SL Academic / other |
| Locations | 1 site (Valencia) |
| Trial ID | NCT05875311 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates a comprehensive telerehabilitation system designed to improve the continuity of care for patients with chronic coronary syndrome. It compares the effectiveness of a telemonitored follow-up approach against standard care in primary care settings. The study aims to assess improvements in physical activity, functional exercise capacity, and adherence to healthy lifestyle practices over a 10-month period. A total of 160 patients will be enrolled, with outcomes measured through the 6-minute walk test and other health indicators.
Who should consider this trial
Good fit: Ideal candidates are patients aged 72 or younger who have experienced an acute coronary syndrome more than one year prior.
Not a fit: Patients with advanced biological age, severe comorbidities, or uncontrolled cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the management and quality of life for patients with chronic coronary syndrome.
How similar studies have performed: Previous studies have shown success with similar telerehabilitation approaches, indicating potential for positive outcomes in this patient population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent * Patients after more than one year of an acute coronary syndrome of both sexes. * Age equal to or less than 72 years. Exclusion Criteria: * Refusal of informed consent * Advanced biological age. * Kidney failure (GFR \< 30ml/min/1.73 m2). * Liver failure (GOT \>2 times normal value). * Ejection fraction less than 50%. * Uncontrolled blood pressure (\>140/90 mmHg). * Uncontrolled heart failure. * Dissecting aortic aneurysm. * Uncontrolled ventricular tachycardia or other dangerous ventricular arrhythmias. * Aortic or mitral valve disease. * Recent systemic or pulmonary embolism. * Active or recent thrombophlebitis. * Acute infectious diseases. * Uncontrolled supraventricular arrhythmias or tachycardia. * Repeated or frequent ventricular ectopic activity. * Moderate pulmonary hypertension. * Ventricular aneurysm. * Uncontrolled diabetes, thyrotoxicosis, myxedema, * Conduction disorders such as: complete atrioventricular block. Left bundle branch block. * Wolf-Parkinson-White syndrome. * Fixed rate pacing. * Severe anaemia. * Psychoneurotic disorders. * Neuromuscular, musculoskeletal and arthritic disorders that may limit activity. may limit activity.
Where this trial is running
Valencia
- Hospital Arnau de Vilanova — Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Ernesto Dalli Peydró, MD — Hospital Arnau de VIlanova. Valencia
- Study coordinator: Ernesto Dalli Peydró, MD
- Email: ernestodallip@gmail.com
- Phone: +34626388083
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.